NEW YORK (GenomeWeb) – Biovica announced today that it has acquired cSens, expanding its portfolio of cancer diagnostic technologies.
Uppsala, Sweden-based Biovica's core offering is DiviTum, a research-use-only ELISA-based biomarker assay that measures the activity of thymidine kinase (TK), an enzymatic biomarker associated with cancer cell proliferation and tumor aggressiveness, in serum or cell culture.
CSens, meanwhile, has developed a PCR-based assay to analyze serum TK activity that Biovica said complements DiviTum and may be used to develop new biomarker assays and tests for cancer and novel drugs.
"The technology complements Biovica well and creates new opportunities for us to provide a faster and more automated platform," Biovica CEO Anders Rylander said in a statement. "Furthermore, we create new opportunities to face new diagnostic needs with the platform and with the expertise of the cSens staff."
Specific terms of the acquisition were not disclosed.